Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMHVJFK)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Cytotec; GyMiso; Isprelor; Misopess; Misoprostolum; Misotol; SC 29333; Cytotec (TN); Misoprostolum [INN-Latin]; SC-29333; XP-16J; Misoprostol (JAN/USAN/INN); Methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
| |||||
| Therapeutic Class | Abortifacient Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Liver
Hepatocellular carcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
